Mixed review for Biotronik's absorbable stent

January 30, 2013 by MassDevice staff

Biotronik touted positive early findings from a 1st-in-man trial of its absorbable metal stent, but researchers say the device need isn't as efficient as it could be.

Biotronik logo

German medical device maker Biotronik touted early findings from a 1st-in-man study of its Dreams absorbable drug-eluting stent, with researchers reporting a mixed bag of findings for the device.

The Dreams stent proved safe at 1 year following the procedure, but wasn't up to par with some rival devices, researchers noted.

Sign up to get our free newsletters delivered right to your inbox.

"Further iterations of the device will need to be designed to improve efficacy," the authors wrote in the trial results, which were published the journal Lancet this month.

Researchers considered 46 patients with lesions in the coronary artery, reporting no deaths or scaffold-related thrombotic events at 12 months.

Rates of target lesion failure at 6 months were comparable to current drug-eluting stents, but weren't as attractive as Abbott's (NYSE:ABT) bioabsorbable stent, which is coated in a different drug.